Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10821801 | 0.94 | L3MBTL1 (0.48) | KMT2ATSHRHTTCA1CA2 | |
| SCHEMBL9121966 | 0.92 | KMT2A (0.51) | KMT2ATSHRHTTCA1CA2 | |
| SCHEMBL3080042 | 0.92 | KMT2A (0.51) | KMT2ATSHRHTTCA1CA2 | |
| SCHEMBL10564876 | 0.92 | KMT2A (0.51) | KMT2ATSHRHTTCA1CA2 | |
| SCHEMBL19749215 | 0.89 | TSHR (0.45) | KMT2ATSHRHTTCA1CA2 | |
| SCHEMBL19067473 | 0.87 | TSHR (0.44) | KMT2ATSHRHTTCA1CA2 | |
| SCHEMBL20254084 | 0.85 | TSHR (0.45) | KMT2ATSHRHTTCA1CA2 | |
| SCHEMBL25078764 | 0.83 | TSHR (0.50) | KMT2ATSHRHTTCA1CA2 | |
| SCHEMBL566016 | 0.83 | TSHR (0.50) | KMT2ATSHRHTTCA1CA2 | |
| SCHEMBL20272903 | 0.83 | L3MBTL1 (0.46) | KMT2ATSHRHTTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449258-B2 | Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2019-10-22 | — | — | US | disclosed |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| EP-3308801-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCExplorer (Shanghai) Co., Ltd. (CN) | 2018-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10449258-B2 | Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof | FCGR3B, SI, INCENP | KMT2A 3529/4885TSHR 3634/4885HTT 3274/4885 |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | FCGR3B, SI, INCENP | KMT2A 3529/4885TSHR 3634/4885HTT 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.